Variant Summary
- Also known as
- THR790MET,RS121434569
- HGVS
- ENST00000275493.2:c.2369C>T,NC_000007.13:g.55249071C>T,NM_005228.4:c.2369C>T,NP_005219.2:p.Thr790Met
- Variant Type(s)
- missense_variant
- Evidence Items
- 30
Evidence Level Distribution
Level A: 3Level B: 11Level C: 4Level D: 11Level E: 1
Evidence Items
Showing CIViC evidence rows where gene = EGFR and variant = T790M.
| Level | Type | Direction | Significance | Disease | Drugs | Rating |
|---|---|---|---|---|---|---|
| A | Predictive | Supports | Sensitivity/Response | Lung Non-small Cell Carcinoma | Osimertinib | 5 |
| A | Predictive | Supports | Sensitivity/Response | Lung Non-small Cell Carcinoma | Osimertinib | 5 |
| A | Predictive | Supports | Resistance | Lung Non-small Cell Carcinoma | Erlotinib | 5 |
| D | Predictive | Supports | Resistance | Lung Cancer | Multikinase Inhibitor AEE788,Gefitinib | 5 |
| B | Predictive | Supports | Resistance | Lung Non-small Cell Carcinoma | Afatinib | 4 |
| C | Predictive | Supports | Resistance | Lung Non-small Cell Carcinoma | Gefitinib,Erlotinib | 4 |
| D | Predictive | Supports | Resistance | Lung Non-small Cell Carcinoma | Lapatinib | 4 |
| B | Predictive | Supports | Resistance | Lung Non-small Cell Carcinoma | Dacomitinib | 4 |
| B | Prognostic | Supports | Poor Outcome | Lung Non-small Cell Carcinoma | 4 | |
| B | Prognostic | Supports | Poor Outcome | Lung Non-small Cell Carcinoma | 4 | |
| B | Predictive | Supports | Sensitivity/Response | Lung Non-small Cell Carcinoma | Rociletinib | 4 |
| B | Predictive | Supports | Sensitivity/Response | Lung Non-small Cell Carcinoma | Osimertinib | 4 |
| B | Predictive | Supports | Resistance | Lung Adenocarcinoma | Gefitinib,Erlotinib | 3 |
| B | Predictive | Supports | Resistance | Lung Non-small Cell Carcinoma | Erlotinib,Gefitinib | 3 |
| B | Predictive | Supports | Resistance | Lung Non-small Cell Carcinoma | Gefitinib | 3 |
| D | Predictive | Supports | Sensitivity/Response | Lung Non-small Cell Carcinoma | Dacomitinib | 3 |
| B | Predictive | Supports | Resistance | Lung Non-small Cell Carcinoma | Gefitinib | 3 |
| C | Predictive | Supports | Sensitivity/Response | Lung Non-small Cell Carcinoma | Erlotinib,Pemetrexed | 3 |
| D | Predictive | Supports | Resistance | Cancer | Gefitinib,Multikinase Inhibitor AEE788,Erlotinib | 3 |
| D | Predictive | Supports | Sensitivity/Response | Lung Non-small Cell Carcinoma | Rociletinib | 3 |
| D | Predictive | Supports | Sensitivity/Response | Lung Non-small Cell Carcinoma | Osimertinib | 3 |
| B | Predictive | Supports | Sensitivity/Response | Lung Non-small Cell Carcinoma | Osimertinib | 3 |
| C | Predictive | Supports | Sensitivity/Response | Lung Adenocarcinoma | Osimertinib | 2 |
| D | Predictive | Supports | Sensitivity/Response | Lung Non-small Cell Carcinoma | Neratinib | 2 |
| D | Predictive | Supports | Sensitivity/Response | Lung Non-small Cell Carcinoma | Afatinib | 2 |
| D | Predictive | Supports | Sensitivity/Response | Lung Non-small Cell Carcinoma | Afatinib | 2 |
| D | Predictive | Supports | Sensitivity/Response | Lung Non-small Cell Carcinoma | Canertinib | 2 |
| C | Predictive | Does Not Support | Sensitivity/Response | Pancreatic Adenocarcinoma | Osimertinib | 2 |
| D | Predictive | Supports | Sensitivity/Response | Lung Non-small Cell Carcinoma | Osimertinib,Rociletinib | 2 |
| E | Predictive | Supports | Sensitivity/Response | Lung Non-small Cell Carcinoma | Staurosporine | 1 |